[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100656982":3},{"organization":4,"outcomesModule":7,"designInfo":40,"detailedDescription":43,"studyPopulation":44,"armGroups":45,"interventions":39,"overallOfficials":52,"centralContacts":56,"locations":65,"responsibleParty":84,"collaborators":39,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":39,"eligibilityCriteria":92,"healthyVolunteers":88,"sex":93,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":39,"studyType":99,"phases":39,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":68,"whyStopped":39,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Beijing Tiantan Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":28,"otherOutcomes":39},[9,13,17,21,24],{"measure":10,"description":11,"timeFrame":12},"Preoperative maximum tumor diameter","Maximum tumor diameter in millimeters, measured on preoperative Magnetic Resonance Imaging (MRI), defined as the largest dimension of the tumor.","Within 3 months before surgery",{"measure":14,"description":15,"timeFrame":16},"Extent of resection","Gross total resection (GTR) versus non-GTR, assessed by intraoperative findings combined with MRI performed within 72 hours after surgery.","Within 72 hours after surgery",{"measure":18,"description":19,"timeFrame":20},"Preoperative symptom phenotype","Presence or absence of preoperative symptoms (including visual decline, headache, hyperpituitarism, hypopituitarism, diplopia, cerebrospinal fluid leak, nonspecific symptoms, and other symptoms) reported by the patient at hospital admission, reflecting symptoms experienced during the preoperative period.","At hospital admission",{"measure":22,"description":23,"timeFrame":20},"Time interval from symptom onset to surgery","Time in months from the date of symptom onset to the date of surgery, calculated from patient-reported history documented in medical records.",{"measure":25,"description":26,"timeFrame":27},"Postoperative hormone remission status","Biochemical remission of functioning adenomas (Prolactin \\[PRL\\], Growth Hormone \\[GH\\], Adrenocorticotropic Hormone \\[ACTH\\], Thyroid-Stimulating Hormone \\[TSH\\]) assessed before hospital discharge, based on disease-specific criteria per Endocrine Society guidelines.","At hospital discharge",[29,32,36],{"measure":30,"description":31,"timeFrame":27},"Length of hospital stay","Number of days from admission to discharge, calculated from medical records.",{"measure":33,"description":34,"timeFrame":35},"Operation duration","Total time of surgery, measured from the start to the end of the procedure, extracted from surgical records.","At the end of surgery",{"measure":37,"description":38,"timeFrame":27},"Total hospitalization costs","Total inpatient expenses in Chinese Yuan (CNY) during the index admission, including all medical services, medications, imaging, laboratory tests, and surgical fees, extracted from hospital billing records.",null,{"allocation":39,"interventionModel":39,"interventionModelDescription":39,"primaryPurpose":39,"observationalModel":41,"timePerspective":42,"maskingInfo":39},"COHORT","RETROSPECTIVE","This multicenter cohort study is based on the National Brain Tumor Registry of China (NBTRC), a nationwide brain tumor registry established by the China National Clinical Research Center for Neurological Diseases.\n\nPatients will be categorized according to their initial consultation department. The screening group will include patients whose tumors were incidentally detected during health screening. The clinical group will include patients diagnosed through outpatient consultations, which will be further subdivided into neurosurgery, ear-nose-throat\u002Fophthalmology, other surgical specialties, and internal medicine. Group assignment will be determined by reviewing each patient's chief complaint, present illness, and past medical history.\n\nThe primary outcomes include surgery-related measures (preoperative maximum tumor diameter and extent of resection, defined as gross total resection) and patient-centered outcomes (preoperative symptom phenotype, time from symptom onset to surgery, and postoperative hormonal remission status before discharge). Secondary outcomes reflect socioeconomic burden, including operation duration, length of stay, and total hospitalization costs.\n\nSubgroup analyses will be performed according to functional hormone subtypes. In addition to the two-group comparison between screening and clinical groups, multi-group comparisons will be conducted across different initial consultation departments, with the screening group serving as the reference. Multivariable regression models will be used to adjust for potential confounders, including age, sex, hormone type, insurance status, and hospital-level clustering.","Patients with PitNETs who underwent surgical resection at Beijing Tiantan Hospital from September 1, 2011, to November 30, 2019, together with those recorded in the NBTRC who underwent surgery from December 1, 2019, to December 31, 2021.",[46,49],{"label":47,"type":39,"description":48,"interventionNames":39},"Clinical group","Tumors were diagnosed at outpatient clinics. For patients in the clinical group, the Initial Consultation Departments will included Neurosurgery, Ear, nose and throat\u002FOphthalmology, Other surgical specialties, and Internal Medicine.",{"label":50,"type":39,"description":51,"interventionNames":39},"Screening group","Tumors were detected by health screening.",[53],{"name":54,"affiliation":5,"role":55},"Wang Jia","PRINCIPAL_INVESTIGATOR",[57,62],{"name":58,"role":59,"phone":60,"phoneExt":39,"email":61},"Luwen Zhang","CONTACT","+86 13051518751","zhangluwen47@163.com",{"name":63,"role":59,"phone":39,"phoneExt":39,"email":64},"Deling Li","lideling@bjtth.org",[66],{"facility":67,"status":68,"city":69,"state":70,"zip":71,"country":72,"countryCode":73,"cosmosGeoPoint":74,"geoPoint":79,"contacts":80},"the National Brain Tumor Registry of China (NBTRC)","RECRUITING","Beijing","Beijing Municipality","100070","China","CN",{"type":75,"coordinates":76},"Point",[77,78],116.39723,39.9075,{"lat":78,"lon":77},[81,82,83],{"name":58,"role":59,"phone":60,"phoneExt":39,"email":61},{"name":63,"role":59,"phone":39,"phoneExt":39,"email":64},{"name":54,"role":55,"phone":39,"phoneExt":39,"email":39},{"type":85,"investigatorFullName":39,"investigatorTitle":39,"investigatorAffiliation":39,"oldNameTitle":39,"oldOrganization":39},"SPONSOR","100656982","a-comparative-study-of-patients-undergoing-surgery-for-pituitary-neuroendocrine-tumors-detected-by-different-ways-100656982",false,"NCT07835412","A Comparative Study of Patients Undergoing Surgery for Pituitary Neuroendocrine Tumors Detected by Different Ways","Role of Health Screening in Patients Undergoing Surgery for Pituitary Neuroendocrine Tumors: A Multicenter Cohort Study From the National Brain Tumor Registry of China (NBTRC)","Inclusion Criteria:\n\n* Patients with PitNETs who underwent surgical resection at Beijing Tiantan Hospital from September 1, 2011, to November 30, 2019, together with those recorded in the NBTRC who underwent surgery from December 1, 2019, to December 31, 2021.\n\nExclusion Criteria:\n\n1. The department (health screening or outpatient clinics) where the definitive diagnosis confirmed was missing or unclear\n2. PitNETs was recurrent or synchronous brain tumors of any histology existed\n3. Admission was via the emergency department\n4. Maximum tumor diameter on preoperative MRI were unavailable\n5. Patients who explicitly declined to participate in this study","ALL","1 Year","85 Years",{"count":97,"type":98},5000,"ESTIMATED","OBSERVATIONAL","This multicenter cohort study is based on the National Brain Tumor Registry of China (NBTRC). It will compare patients who underwent surgery for Pituitary Neuroendocrine Tumors (PitNETs) detected through health screening versus those diagnosed via outpatient consultations. The study will evaluate differences between the two groups in surgical metrics, patient-centered outcomes, and healthcare utilization.",[102],"Pituitary Neuroendocrine Tumors",[102,104,105,106,107],"Health Screening","Patient-Centered","Hormone Remission","Extent of Resection","2026-09-28",{"date":110,"type":111},"2026-09-30","ACTUAL",{"date":113,"type":111},"2026-09-22",{"date":110,"type":98},{"name":5,"class":6},1]